Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/06/26	2.087 $	+2.80%	58,416
16/06/26	2.030 $	-0.98%	52,921
15/06/26	2.050 $	+1.49%	120,856
12/06/26	2.020 $	+1.51%	1,203,545
11/06/26	1.990 $	+2.05%	49,882

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.030USD

Average target price

9.978USD

Spread / Average Target

+391.50%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 21:23:14 17/06/2026 +03			5-day change	1st Jan Change
2.087 ^USD	+2.80%		+7.02%	-65.90%

06-09	Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma	MT
06-01	Actuate Therapeutics, Inc. Presents Clinical And Biomarker Data For Elraglusib In First-Line Metastatic Pancreatic Cancer At ASCO	CI

Market Cap	48.57M 41.9M 38.52M 36.26M 68.13M 4.58B 68.71M 457M 178M 2.25B 182M 178M 7.78B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	48.57M 41.9M 38.52M 36.26M 68.13M 4.58B 68.71M 457M 178M 2.25B 182M 178M 7.78B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	84.64%	Yield 2026 *	-	Yield 2027 *	-

06-09	Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma	MT
06-01	Actuate Therapeutics, Inc. Presents Clinical And Biomarker Data For Elraglusib In First-Line Metastatic Pancreatic Cancer At ASCO	CI
05-14	Actuate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-11	Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program	CI
05-06	Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026	CI
04-22	HEALTH ROUNDS-Actuate Therapeutics drug improves survival odds in pancreatic cancer trial	RE
04-15	B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating	MT
04-14	Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	CI
03-27	Actuate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Actuate Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-21	Actuate Therapeutics announces plans to expand clinical pipeline, advancing elraglusib tablet into a phase 1/2 clinical program in refractory cancers	RE
01-21	Actuate Therapeutics, Inc. Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into A Phase 1/2 Clinical Program in Refractory Cancers	CI
01-13	Actuate Therapeutics Inc - Reports positive phase 2 trial data for elraglusib - SEC filing	RE

04-15	B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating	MT
26/08/25	B. Riley Initiates Actuate Therapeutics With Buy Rating, $20 Price Target	MT

Actuate Therapeutics, Inc. Stock

Stocks

ACTU

US0050831009

Biotechnology & Medical Research

Valuation: Actuate Therapeutics, Inc.

Chart: Actuate Therapeutics, Inc.

Latest news : Actuate Therapeutics, Inc.

Last Transcript: Actuate Therapeutics, Inc.

Analysts' recommendations: Actuate Therapeutics, Inc.

Press Releases: Actuate Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Actuate Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

06-09	Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma	AQ
06-01	Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer	AQ
05-11	Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program	AQ
05-06	Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors	AQ
04-14	Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	AQ

1 day	+4.43%
1 week	+7.02%
Current month	+3.31%
1 month	-14.12%
3 months	-24.66%
6 months	-69.58%
Current year	-65.90%

1 week	1.85	2.78
1 month	1.77	2.81
Current year	1.58	7.05
1 year	1.58	9.22
3 years	1.58	11.99
5 years	1.58	11.99
10 years	1.58	11.99

Manager	Title	Age	Since
Daniel Schmitt CEO	Chief Executive Officer	64	01/03/2015
Paul Lytle DFI	Director of Finance/CFO	58	01/02/2024
Andrew Mazar COO	Chief Operating Officer	64	01/06/2022

Director	Title	Age	Since
Daniel Schmitt BRD	Director/Board Member	64	01/04/2015
Aaron Fletcher CHM	Chairman	45	01/04/2015
Daniel Zabrowski BRD	Director/Board Member	66	01/03/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-21	Daniel Zabrowski	Free	Director	15,000	0.0633%
05-21	Amy Ronneberg	Free	Director	15,000	0.0633%
05-21	Jason Keyes	Free	Director	15,000	0.0633%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTUATE THERAPEUTICS, INC.	+2.80%	+7.02%	-73.14%	-	48.57M
ARGENX SE	+3.23%	+2.25%	+65.02%	+116.66%	54.54B
WUXI APPTEC CO., LTD.	+0.04%	+5.05%	+43.44%	+36.75%	43.86B
BIONTECH SE	+3.70%	+7.58%	-11.71%	-15.70%	22.63B
INSMED INCORPORATED	+2.91%	+6.73%	-2.21%	+385.21%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	-0.27%	+12.68%	-37.07%	15.84B
GENMAB A/S	+5.27%	+1.87%	+13.67%	-38.00%	14.83B
EXELIXIS, INC.	+1.62%	+0.25%	+27.46%	+178.30%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+4.13%	+13.12%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	-0.20%	+6.00%	+78.69%	+103.53%	11.56B
Average	+1.53%	+0.26%	+16.70%	+91.21%	20.98B
Weighted average by Cap.	+1.65%	+0.18%	+33.25%	+91.22%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-